Pediatric Oncology II

Oncoletter provides you with quotes from the abstract's conclusions. To see more, go the ASCO Meeting Library while clicking on the link of the study-titles (to see videos and slides needs a payable registration)

 
Reuven J. Schore, Anne J. Angiolillo, John A Kairalla, et al.
 
The abstract concludes: 
AALL0932 demonstrated that application of stringent risk criteria can identify a favorable B-ALL subgroup almost certain to be cured with either LR-M or LR-C, allowing physicians and families to select the optimal treatment approach in the future. Clinical trial information: NCT01190930
--------------------------------------------------------------------------------------------------------------------------------------------------------
 
 
Karen R. Rabin, Zhiguo Chen, Meenakshi Devidas, et al.
 
The abstract concludes: 
Patients with DS and B-ALL continue to have inferior outcomes compared to non-DS, with increased relapse and toxicities. Less toxic approaches such as immunotherapies and targeted therapies hold promise to improve outcomes in both these areas.

U.S. National Institutes of Health

--------------------------------------------------------------------------------------------------------------------------------------------------------
 
 
Haley Newman, Allison Emily Barz Leahy, et al.
 
The abstract concludes: 
The CD19 CAR T cell therapies CTL019/CTL119 are effective at clearing CNS disease and inducing durable remissions in children and young adults with r/r CNS B-ALL. CNS relapse rates are low ( < 3%). Most CD19 CAR T cell trials excluded patients with active CNS disease, primarily due to the risk of NT. We show that patients with r/r CNS B-ALL that is adequately controlled prior to infusion can be safely treated with CD19 CAR T cells, with no increased risk of NT. Clinical trial information: NCT01626495, NCT02435849, NCT02374333, NCT02906371
--------------------------------------------------------------------------------------------------------------------------------------------------------
 
 
Susan R. Rheingold, Lewis B. Silverman, James A. Whitlock, et al.
 
The abstract concludes: 
Temsirolimus at 25 mg/m2 combined with salvage etoposide and cyclophosphamide has an acceptable safety profile in high-risk pediatric patients with r/r ALL. Responses were observed at all DLs. mTOR target inhibition was achieved and appeared to correlate with dose level. Future testing of other PI3K/mTOR pathway inhibitors in combination with chemotherapy may be warranted with a goal of further increasing response in r/r ALL. Clinical trial information: NCT01614197

Pfizer IIB mechanism Other Foundation

--------------------------------------------------------------------------------------------------------------------------------------------------------

 
Eric Jessen Chow, Sanjeev Aggarwal, David R Doody, et al.
 
The abstract concludes: 

After >17y, childhood cancer survivors treated with DOX+DRZ had better LV systolic function and less myocardial wall stress compared with those treated with DOX alone. DRZ may preferentially benefit females and those treated with greater DOX doses.

U.S. National Institutes of Health Other Foundation

--------------------------------------------------------------------------------------------------------------------------------------------------------

The abstract concludes: 

Childhood cancer survivors of African ancestry are at higher risk of cardiomyopathy than those of European ancestry. Dysregulation of PHTF1 may represent the molecular mechanism underlying the rs6689879-cardiomyopathy association. These findings have potential implications for long-term cardiac surveillance as well as up front cancer care for patients of African descent.

U.S. National Institutes of Health the Leukemia and Lymphoma Society and the American Lebanese Syrian Associated Charities, Memphis, Tennessee

--------------------------------------------------------------------------------------------------------------------------------------------------------
 
 
Eric Jessen Chow, Yan Chen, Gregory T. Armstrong, et al.
 
The abstract concludes: 

CVRF underdiagnosis and undertreatment among childhood cancer survivors at increased risk of heart disease was common. Greater awareness among survivors and primary care providers and more aggressive control of CVRFs may mitigate this risk.

U.S. National Institutes of Health Other Foundation

--------------------------------------------------------------------------------------------------------------------------------------------------------
 
 
The abstract concludes: 
Upfront TEMIRI x 2 courses showed an encouraging activity, with response rate 59% and deserves further evaluation combined with conventional treatments also in non-metastatic patients. In PMES new treatment strategies are urgently needed. Clinical trial information: NCT02727387
--------------------------------------------------------------------------------------------------------------------------------------------------------
 
 
Nadia Puma, Asaftei Dorin Sebastian, Anna Paioli, et al.
 
The abstract concludes: 
This schedule of maintenance phase is feasible, despite previous intensive treatment. A longer follow-up is needed to monitor side effects and to evaluate clinical outcome of patients with lung or single bone metastases, while the outcome remains dismal for multicentric metastatic Ewing sarcoma. Clinical trial information: NCT02727387